Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2023-03-22 Annual Report (ESEF)
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Document d'enregistrement universel 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-03-22 French
Février 2023 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Share Issue/Capital Change Classification · 95% confidence The document is a short, formal notification from bioMérieux, dated March 7, 2023, detailing the total number of shares and voting rights as of February 28, 2023. It explicitly references French regulatory articles (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation). This type of monthly disclosure regarding share capital and voting rights is a standard regulatory requirement, often related to capital structure changes or general shareholder information. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific regulatory filing concerning share structure/voting rights that doesn't fit perfectly into the other specific categories like DIRS or SHA (which usually announce a transaction), it falls best under the general regulatory announcement category, RNS, or potentially a specific capital/share structure notification. Given the context of monthly voting rights disclosure, it is a mandatory regulatory filing. While SHA relates to share issues, this is a periodic report on existing rights. RNS is the most appropriate fallback for mandatory, non-core financial disclosures that don't match other specific types. However, since it is a direct report on the number of shares and voting rights, it is closely related to capital structure reporting. Given the options, RNS (Regulatory Filings) is the safest general classification for mandatory periodic regulatory updates not covered elsewhere. The document length is very short (1800 chars), suggesting it is a direct filing rather than a comprehensive report.
2023-03-10 French
BioFire Defense partners with BARDA to accelerate development of the Specific Diagnostics SPECIFIC REVEAL™ Rapid AST System
Regulatory Filings Classification · 100% confidence The document is a press release dated March 10, 2023, announcing that BioFire Defense (an affiliate of bioMérieux) received a contract from BARDA to accelerate the development of a diagnostic system. It details the scope of the contract, funding sources, and includes quotes from management and boilerplate 'About Us' sections, concluding with investor and media contact information. This format is characteristic of an official company announcement regarding a significant business development (a government contract). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed financial report (IR). Since it announces a specific business development/contract award, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, although it is more specific than a typical RNS. Given the options, and since it's not a financial report, management change, or capital event, RNS serves as the most appropriate general announcement category for this type of news release.
2023-03-10 English
BioFire Defense s'associe avec la BARDA pour accélérer le développement du système d'antibiogramme rapide SPECIFIC REVEAL™ de Specific Diagnostics
Regulatory Filings Classification · 91% confidence The document is a press release dated March 10, 2023, announcing that bioMérieux's subsidiary, BioFire Defense, has secured a contract with BARDA (Biomedical Advanced Research and Development Authority) to accelerate the development of a rapid antimicrobial susceptibility testing system. This type of announcement, detailing a specific business development, contract award, or partnership, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate announcement regarding business operations and government contracts. Since it is not a transcript (CT), a management discussion (MDA), or a formal regulatory filing like a proxy statement (DEF 14A), the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate news releases, or potentially a general 'LTR' if the contract itself is considered a regulatory/government interaction, but RNS is the better fit for a general press release about a contract award.
2023-03-10 French
bioMérieux – 2022 Financial Results
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – 2022 Financial Results" and contains detailed consolidated financial statements, including Net Sales, Contributive operating income, and Net income for the twelve months ended December 31, 2022. It explicitly states that the Board of Directors approved the audited consolidated financial statements for the year ending December 31, 2022, on March 7, 2023. This content structure—full-year financial performance, detailed segment breakdowns, and management commentary on the full year—is characteristic of an Annual Report or a comprehensive earnings release that often precedes or substitutes for the 10-K filing, but given the depth and the reference to 'audited consolidated financial statements for the year ending December 31, 2022,' it strongly suggests the primary annual financial disclosure. Since the document provides the full audited annual figures and comprehensive analysis, it aligns best with the scope of a 10-K, which is the official yearly report covering full financial performance. It is more detailed than a typical Earnings Release (ER) and is not just a short announcement (RPA). FY 2022
2023-03-08 English
bioMérieux - Résultats annuels au 31 décembre 2022
Earnings Release Classification · 100% confidence The document is titled "bioMérieux – Résultats annuels au 31 décembre 2022" (Annual Results as of December 31, 2022). It contains detailed financial tables showing consolidated accounts for 2022 and 2021, including revenue, operating income, and net income. It also provides forward-looking guidance for 2023 and a statement from the CEO. The text explicitly mentions that the Board of Directors "a arrêté les comptes consolidés audités du Groupe au 31 décembre 2022" (approved the audited consolidated accounts of the Group as of December 31, 2022). This content structure—full-year audited results, detailed segment breakdowns, and outlook—is characteristic of a comprehensive Annual Report, which corresponds to the 10-K filing type in the US context, or the primary annual financial disclosure. Although it is in French, the content aligns perfectly with the definition of an Annual Report (10-K). It is not merely an Earnings Release (ER) as it is comprehensive and includes audited figures, nor is it a short announcement (RPA/RNS). FY 2022
2023-03-08 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.